Evogene Ltd.

Foreign Filer Report • Jan 18, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2022

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

On January 18, 2022, Evogene Ltd., or Evogene, announced positive results in pre-clinical studies in the Precise product program for medical cannabis of its subsidiary Canonic Ltd., or Canonic. A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K, and is incorporated herein by reference.

In addition, an updated Canonic investor presentation is furnished as Exhibit 99.2 to this Form 6-K.

The contents of Exhibit 99.1 to this Form 6-K, excluding the statements of Canonic's CEO and of its advisor, are incorporated by reference into the registration statements on Form F-3 (File No. 333-253300) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: January 18, 2022

By: /s/ Dorit Kreiner

Dorit Kreiner Chief Financial Officer

——————————————

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1Press Release: Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis.

99.2Canonic Investor Presentation.

Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis

The results support the successful identification of specific cannabis varieties with anti- inflammatory and pain relief properties, for which Canonic recently filed a patent application

Rehovot, Israel – January 18, 2022 – Canonic Ltd., focused on the development of medical grade cannabis products and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), announced today positive results in pre- clinical studies in inflammatory and pain model systems conducted in Israel by Hadassah Medical Center in Jerusalem and by Migal - Galilee Research Institute in Kiryat Shmona. The results support the identification of specific cannabis varieties with heightened anti-inflammatory and pain relief properties for Canonic's medical cannabis Precise product line and have led to a patent application filing.

In its Precise product line, Canonic aims to develop medical grade cannabis inflorescence and oil products that provide relief for patients for specific medical indications with a high level of consistency and specificity in its clinical effects. Canonic's first product candidates within the Precise program target pain relief and inflammation reduction and are planned to be launched in Israel during 2023, followed by a European expansion.

According to industry estimates, the medical cannabis market in Europe is estimated to pass €1 billion in 2023. According to a broad health economic study run by the BfArM1 conducted in Germany, which represents over 50% of the European market, pain relief was the most frequently treated medical indication representing more than 70% of the medical indications treated with medical cannabis or cannabis-based medicines2. The Israeli medical cannabis market includes over 105,000 licensed patients and is estimated at \$260 million per year, with over 60% of medical cannabis in Israel prescribed for pain and inflammation indications³.

2 https://pubmed.ncbi.nlm.nih.gov/33564897/; https://www.aerzteblatt.de/int/archive/article/218127/Interim-results-of-the-survey-accompanying-the-prescription-of-cannabis-based-medicines-in-Germany-regarding-dronabinol 3 Please note the sources are in Hebrew: https://www.health.gov.il/Subjects/cannabis/Documents/licenses-status-december-2021.pdf; https://finance.walla.co.il/item/3428846

¹ The Federal Institute for Drugs and Medical Devices in Germany (https://www.bfarm.de/EN/Home/_node.html)

In the pre-clinical studies reported today, Canonic screened multiple cannabis lines from its diverse genetic collection for anti-inflammatory and pain relief properties. These lines had been selected according to active compounds compositions by using Evogene's GeneRator AI tech engine. The screening of these selected lines was conducted in two separate models – in an in-vitro model at the laboratory of Prof. Reuven Or at the Hadassah Medical Center and in an in-vivo (fish larvae) model at Migal - Galilee Research Institute. Several varieties, including the cannabis variety which is the basis for Canonic's product G150⁴, exhibited consistent positive results in both model systems, over several repetitions and independent cultivation cycles. Based on these results, Canonic has filed a patent application for several of these cannabis varieties and their medical effects.

Canonic expects to continue the development of these best performing varieties during 2022, including the gathering of clinical data, in expectation of commercializing its first Precise products in 2023 in Israel, with expansion into Europe planned to follow.

Canonic recently strengthened its management team with the recruitment of Ms. Tanya Damm Bokobza, EVP Business Development, and Dr. Haleli Sharir, Clinical Research Director. Their engagement with Canonic will support the plans for commercial expansion in Israel and Europe and clinical research activities. Canonic also published an updated investor presentation, which can be found here⁵.

Prof. Yossi (Joseph) Tam, Managing Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem & Advisor to Canonic, stated: "We would all like to think that cannabis represents a potential solution for specific, difficult to treat, medical conditions, such as pain or inflammatory diseases, for which we lack ideal treatments. After all, it would be poetic if nature's wisdom provided the medicine we have not yet designed ourselves. The ability of Canonic's medical cannabis varieties in reducing pain and inflammation in pre-clinical settings is impressive. Indeed, breeding whole cannabis plants such that they contain specific compounds in specific quantities and tailored ratios in order to hit the right disease targets with minimal adverse events is what we should aim for in order to benefit our society. And this is exactly what Canonic does."

⁴ For more information, please see: https://canonic.co.il/g150/. Please note that the page is in Hebrew. 5 http://www.evogene.com/wp-content/uploads/2022/01/Canonic-Company-Presentation_Jan2022_FINAL.pdf

Dr. Arnon Heyman, CEO of Canonic, stated: "We are pleased with the progress achieved in these pre-clinical studies, which now allow us to advance the development of our first products in the Precise medical cannabis line. These results demonstrate further confirmation for the power of the computational biology platform that we use, supported by Evogene's GeneRator AI tech engine. I would like to thank our partners at Hadassah Medical Center and Migal - Galilee Research Institute and I look forward to continuing the development of our novel products. I believe that the global cannabis market is moving in the direction of products backed by clinical data supporting the consistency of medical relief for patients. These are precisely the type of products Canonic is developing in its Precise program. We look forward to updating as we advance towards commercialization."

About Canonic Ltd.:

Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), developing medical Cannabis products utilizing a Computational Predictive Biology (CPB) platform. The Company's products in development are aimed at improving active compounds yield, genetic stability and Cannabis varieties for specific medical indications. The Company's strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene's genomic assets and technology for the development of medical Cannabis products. For more information, please visit: https://www.canonicbio.com/.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag. Ltd. For more information, please visit: www.evogene.com.

Forward Looking Statements:

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates", "aims" or words of similar meaning. For example, Evogene and Canonic are using forward-looking statements in this press release when they discuss Canonic's product development efforts and commercialization plans for its Precise product line, the potential benefits of Canonic's products and product candidates, and the expected growth in the cannabis market and number of patients. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene's reports filed with applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact:

Rivka Neufeld Investor Relations E: IR@evogene.com T: +972-8-931-1940

US Investor Relations:

• Joseph Green Edison Group E: jgreen@edisongroup.com T: +1 646-653-7030
• Laine Yonker Edison Group E: lyonker@edisongroup.com T: +1 646-653-7035

Forward Looking Statement

This presentation contains "forward-looking to future events, and Canonic Ltd (the "Company") and its parent, Evogene U.d. ("Evogene"), nay from time to time make other statements, regarding for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defines Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as anended. Statements that are not statements of historical forward-looking statements. Such forward-looking statements may be identified w the use of such words as "believe", "anticipate", "should", "planned", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we divers, commercialization efforts and timing, product development and launches sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expections and assumptions, describe opinions about future events, involve certain risks and uncerainties which are difficult to predict and are not guarante. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ naterially from what is expressed or implied by such for a variety of factors, many of which are beyond our control, including, without limitation, those detail in Evogene's Anual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws obligation or commitment to update any information or to publicy release the results of any revisions to any statements that meets or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not on other offering document, nor does it constitute or form part of any invitation of offer o sell, or any solicitation of any invitation or offer to purchase or securities of Evogene or the Company, nor shall the information or any part of its of the fact of its distribution for the basis of or be relied on in contract, contract, contract, commitment or relating the securities of Evogene of the Company.

The trademarks included herein are the property of the owners only Such use should not be construed as an endorsement of our products or services.

(A) CANONIC

OUR VISION

Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect

Legal Cannabis Worldwide: \$46.8 Billion in 2025

Market Challenges

STABILITY Substantial variations within varieties produce inconsistent products and therefore, inconsistent results

YIELD

Low yield of active compounds affects income per sq foot

SPECIFICITY

Significant knowledge gap prevents matching active compounds to medical indications

The opportunity: With state-of-the-art plant genomic expertise, major market challenges can be solved

The opportunity From Plant Genetics - To Medical Cannabis Products

Plant genetics know-how is the basis for development of premium Cannabis varieties

Premium varieties can lead to novel medical Cannabis products addressing market challenges

---

Variety Families Under Development

Meta Yield+

Stable enhancement of total plant compounds Focus on agronomic and consumer traits

Precise+

Stable enhancement of specific active compounds Focus on therapeutic traits

Increased active compounds [e.g. Increased trichomes prevalence]

Optimize consumer traits [e.g. inflorescence size, density, scent]

First products in the market

CA CANONIC

Compound profile focus [e.g. CBG, CBC]

Medical indication focus

[e.g. Pain & Inflammation]

Next generation products

MetaYield+ Varieties - The G-nnovation series

Now available in more than 70 pharmacies in Israel

Precise *: Medical indication focus

Report Feb 2020.

(A) CANONIC

ic LTD

Precise *: Specific compound profile

Collaboration With Tikun Olam-Cannbit

TIKUN®OLAM MEDICAL CANNABIS CANNBIT PHARMACEUTICALS LTD

(@) CANONIC __________________________________________________________________________________________________________________________________________________________________

The Genomic Power - improving performance

The potential: Improving plant traits through advanced breeding

Example -

Corn is considered a leading commercial crop Wild corn went through genetic changes before it became a commercial crop.

The challenge:

Connect genomic elements to traits Shorten the development time

The opportunity => BIG DATA AND COMPUTATIONAL BIOLOGY

(@ CANONIC ___________________________________________________________________________________________________________________________________________________________________

When Data Meets Computational Biology

Computational Genomics

Combining deep scientific know-how with Big Data and AI technology to tailor the plant genetics for improvement of plant traits and development of unique cannabis products

@ CANONIC ____________________________________________________________________________________________________________________________________________________________________

All right reserved to Canonic LTD.

Canonic proprietary database and assets

Big Data & Al transforming Data to Know-how

The genomic power - 20% increase in THC content

Developing next generation MetaYield+ products

By leveraging our unique proprietary know-how and database, within 12 months we have:

• Improved the target trait by 20%
• Reached 6-fold increase in number of cannabis lines with >20% THC content

Demonstrated Capabilities Along The Development Value Chain

Cannabis Value Chain

Seed to Sale Powered by Genomics

Canonic in the Cannabis Value Chain

Reduced time to market and higher profitability by leveraging our proprietary genomic expertise and outsourcing downstream elements of the value chain

Team

Dr. Arnon Heyman CEO

Tanya Damm Bokobza EVP Business Development

Dr. Inbal Dangoor VP R&D

Guy Adler VP Product

Elena Huly Marketing & Sales

---

Yonatan Wegman

Head Agronomist

Dr. Michi Brog

Plant Breeder

Dr. Haleli Sharir Clinical Research Director

Directors and Advisory Board

Board of directors

Ofer Haviv Chairman of the board Evogene President & CEO

Raanan Cohen Business strategy Former CEO Koor Industries

Prof. Yossi Tam Cannabinoid clinical research

Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew University

Advisory board

Nirit Elyovich Marketing strategy

Senior marketing specialist with over 20 years of B2C experience

Omri Ofer Pharmaceutical distribution

Former CEO Chemipal

Dorit Kreiner Finance

Evogene CFO

CANONIC

Dr. Yariv Brotman Plant metabolic pathways

Ben Gurion University & Max Planck Institute of Molecular Plant Physiology

Shai Leviatov Plant breeding

Commercial varieties breeding for more than 30 years in top leading multinational seeds companies

All right reserved to Canonic LTD.

Company Milestones

Summary

• · Canonic's distinct market advantage is in mapping, decoding and stabilizing cannabis genetics for better health.
• · Canonic holds exclusive rights to Evogene's (NASDAQ, TASE: EVGN) state-of-the-art computational genomics technology, for product development for the Cannabis market segment.
• · Canonic's first two products, G-150 and G-200, were launched in Israel in October 2021.
• · Next generation products are expected to focus on 2 major medical indications, pain and inflammation, which represent > 60% of the medical market*.
• · Canonicaims to enter the EU market during 2023.

*Company estimate, based on data published by Israel Ministry of Health regarding number of medical cannabis users in Israel